Medication info
Olodujet Tablets 20/20 mg

Olodujet Tablets 20/20 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
White or yellowish round film-coated tablets
Packaging
30 tablets/box [10 tablets/Alu-Alu*3]
Approval status
Active

MFDS item code 202003974 · Approved 2020.05.28

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, suppression of atherosclerotic progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.
Child dose
Safety and efficacy have not been established in children under 18 years of age.

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, suppression of atherosclerotic progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who need to take both olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil helps treat essential hypertension. Rosuvastatin is used as an adjunct when hypercholesterolemia and mixed dyslipidemia cannot be controlled by diet and exercise, and it is effective for familial hypercholesterolemia as well. Furthermore, rosuvastatin lowers total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis and reducing the risk of cardiovascular disease. Especially in middle-aged individuals with cardiovascular risk factors, it contributes to reducing the risk of complications such as stroke, myocardial infarction, and revascularization procedures. This medication is used to improve cardiovascular health by managing hypertension and dyslipidemia concurrently.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.

Child dose

Safety and efficacy have not been established in children under 18 years of age.

Precautions

This medication may cause serious harm to a fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. This medication is contraindicated for certain patients. For example, it should not be used in individuals allergic to this medication or its components, pregnant or potentially pregnant women, nursing mothers, patients with severely impaired kidney function, patients with severely impaired liver function, and patients with certain muscle disorders. Care should be taken when initiating this medication in patients with low blood pressure or low salt levels, as hypotension may occur. Patients with compromised kidney function should have their kidney function and electrolyte status monitored regularly with blood tests. This medication may cause muscle pain, muscle weakness, and rarely, severe muscle damage (rhabdomyolysis); therefore, patients should consult a doctor immediately if they experience any abnormal muscle symptoms. Abnormal liver function may occur while taking this medication, so liver function tests before and during treatment are recommended. Dizziness or drowsiness may occur, so caution is advised when driving or operating dangerous machinery. This medication may interact with other drugs, so it is essential to inform your doctor or pharmacist if you are taking other medications, especially potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, certain antibiotics or antifungals, and fibrate medications. Pregnant or nursing women should not use this medication, and women planning to become pregnant should use appropriate contraception. Safety and efficacy in children under 18 have not been established, so its use is not recommended in this age group. Elderly patients may have elevated blood concentrations of this medication, so dose adjustments and caution are required. In case of overdose, symptoms such as hypotension and heart arrhythmias may occur, and immediate medical attention is necessary, as there is no specific antidote, and treatment may be required based on symptoms. This medication should be kept out of the reach of children, and it is safer not to transfer it into another container.

Side effects

Increased ALT, increased AST, elevated blood creatinine, decreased creatinine clearance, headache, dizziness, sensory disturbance, neuromyopathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, dental extraction, thoracic pain, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, asthenia, vascular edema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional dizziness), palpitations, elevated blood pressure, low back pain, increased blood creatinine, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reaction including vascular edema, diabetes, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe myasthenia gravis, ocular myasthenia gravis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, at a temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its effectiveness and safety.

Appearance and packaging

Appearance

White or yellowish round film-coated tablets

Package unit

30 tablets/box [10 tablets/Alu-Alu*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.